BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study

Germline BRCA1/2 testing of breast and ovarian cancer patients is growing rapidly as the result affects both treatment and cancer prevention in patients and relatives. Through the DNA-BONus study we offered BRCA1/2 testing and familial risk assessment to all new patients with breast (N=893) or ovari...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Eur J Hum Genet
Auteurs principaux: Høberg-Vetti, Hildegunn, Bjorvatn, Cathrine, Fiane, Bent E, Aas, Turid, Woie, Kathrine, Espelid, Helge, Rusken, Tone, Eikesdal, Hans Petter, Listøl, Wenche, Haavind, Marianne T, Knappskog, Per M, Haukanes, Bjørn Ivar, Steen, Vidar M, Hoogerbrugge, Nicoline
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4867439/
https://ncbi.nlm.nih.gov/pubmed/26350514
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ejhg.2015.196
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires